Carvedilol and its combination with digoxin for heart rate control in patients with persistent atrial fibrillation and chronic heart failure
Abstract
Aim. To compare effectiveness of carvedilol as monotherapy and in combination with digoxin for heart rate (HR) control in patients with persistent atrial fibrillation (AF) and chronic heart failure (CHF). Material and methods. In total, 45 men and women, aged 42-77 years, with persistent AF and NYHA Functional Class II-III CHF were randomized into two treatment groups, and sub-divided by baseline ejection fraction, EF (EF>45%; EF<45%) and HR (HRMOO; HR<100 bpm). Clinical and hemodynamic parameters, as well as beta-adrenoreactivity were assessed during the study. Results. The most manifested clinical signs of myocardial contractility improvement were observed in combined therapy group. At the same time, in patients with EF>45%, non-significant benefits of carvedilol monotherapy were registered. Conclusion. In CFH patients with persistent AF and baseline EF>45%, carvedilol monotherapy was more effective; in EF>45%, combined therapy had more clinical benefits. Moreover, combined therapy was more effective in baseline HRMOO, and carvedilol monotherapy - in baseline HR<100.
About the Authors
S. N. Tereshchenko
Moscow State Medico/Stomatological University. Moscow
Russian Federation
Russian Federation
N. G. Chuich
Moscow State Medico/Stomatological University. Moscow
Russian Federation
Russian Federation
M. N. Morozova
Moscow State Medico/Stomatological University. Moscow
Russian Federation
Russian Federation
A. G. Kochetkov
Moscow State Medico/Stomatological University. Moscow
Russian Federation
Russian Federation
References
1. Khaud A., Cleland J., Deedwania P. Prevention of and medical therapy for atrial arrhythmias in heart failure. Rev 2002; 7: 267-83.
2. Levy S., Maarek M., Coumel P., et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA stady Circulation 1999; 99: 3028-35.
3. Godtfredsen J., Falk R. Cardiac arrhythmias. A clinical approach. St. Louis etc.: Mosby 2003; 452.
4. Hobbs W.J., Van Gelder I.С., Fitzpatrick A.P., et al. Lhe role of atrial electrical remodeling in the progression of focal atrial ectopy to persistent atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 866-70.
5. Недоступ А.В., Благова О.В., Богданова Э.А., Платонова АА. Коррекция частоты и структуры желудочкового ритма при постоянной форме мерцательной аритмии: новый патогенетический подход. Кардиология 2004; 1: 31-8.
6. Cleland.J, Chattopadhyay S., Khaud A., et al. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002; 7: 229-42.
7. Dries D., Exner D., Gersh B. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analisis of the SOLVD trials. JACC 1998; 32: 695-703.
8. Сидоренко Б.А., Преображенский Д.В., Шарошина И.А. и др. Место сердечных гликозидов в лечении хронической сердечной недостаточности. Часть П. Результаты небольших исследований. Кардиология 2005; 5: 78-91.
9. Peter R. A review of carvedilol arrhythmia data in clinical trials. J Cardiovasc Pharmacol Lher 2005; 10: S59-68.
10. Джагессар Д., Павликова Е.П., Мерай И. и др. Влияние карведилола и метопролола на переносимость физической нагрузки, перекисное окисление липидов и среднемолекулярные токсины у больных ХСН. Клин фармак тер 2003; 4: 43-6.
11. Kennedy Н. Beta-blocker prevention of proarrhythmia and pro-ischemia. Clues from CASL, САМ1АГ and EMIAT. Am J Cardiol 1997; 80: 1208-11.
12. Национальные рекомендации по диагностике и лечению ХСН. Серд недост 2003; 4(6): 276-97.
13. Моисеева B.C. Сердечная недостаточность и аритмии. Фибрилляция предсердий. Клин фармак тер 2003; 4: 9-11.
14. Krum H., Bigger J.L., Goldsmith R.L., Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. JACC 1996; 28: 813-9.
15. Newton G.E., Long J.H., Schoficld A.M, et al. Digoxin reduces cardiac sympathetic activity in severe heart failure. JACC 1996; 28: 155-61.
16. Eichhorn E.J., Domanski M., Krause-Steinrauf H., et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-67.
17. Терещенко C.H., Буланова Н.А., Косицина И.В. и др. Хроническая сердечная недостаточность и фибрилляция предсердий: особенности лечения. Кардиология 2003; 10: 87-92.
18. Терещенко C.H., Демидова И.В., Борисов Н.Е., Моисеев B.C. Клинико-гемодинамическая эффективность карведилола у больных застойной сердечной недостаточностью. Кардиология 1998; 2: 43-6.
19. Стрюк Р.И., Длусская И.Г. Адренореактивность и сердечно-сосудистая система. Москва 2003.
20. Стрюк Р.И., Длусская И.Е Новый метод прогнозирования и оценки эффективности бета-адреноблокаторов у больных гипертонической болезнью. Кардиология 1997; 8: 10-3.
Review
For citations:
Tereshchenko S.N., Chuich N.G., Morozova M.N., Kochetkov A.G. Carvedilol and its combination with digoxin for heart rate control in patients with persistent atrial fibrillation and chronic heart failure. Cardiovascular Therapy and Prevention. 2006;5(7):62-68. (In Russ.)
Views:
2368
Email this article 
